Loading
A phase 3 trial of Oxaliplatin, Tegafur, gimeracil and oteracil and Capecitabine in Colorectal cancer, run by Peking University Cancer Hospital & Institute, with a status the registry has not verified recently.
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients is a phase 3 interventional study registered as NCT03448549 by Peking University Cancer Hospital & Institute, with 1191 participants planned, started 2018-01-01 and due to reach its primary completion in 2021-01-01. Interventions recorded: Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda. Conditions recorded: Colorectal Cancer Stage III, Adjuvant Chemotherapy.
Linked to the drug Tegafur, gimeracil and oteracil because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tegafur, gimeracil and oteracil (S-1), Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Colorectal cancer and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/